AbbVie has joined the ranks of pharma groups trying to develop weight-loss drugs, licensing a long-acting amylin analogue from Denmark's Gubra in a deal valued at more than $2.2 billion.

This Big Pharma stock is one of the safest bets, according to the Mad Money host, and it plays an attractive dividend to ...

Boehringer Ingelheim and partner Zealand Pharma have reported new clinical data in obesity for their dual glucagon/GLP1 agonist BI 456906, setting up a possible challenge to emerging therapies ...

AbbVie ABBV stock has risen 8.0% in six months, adding more than $24 billion to its market value. AbbVie has successfully ...

Gubra Q1 2025 slides: $2.2B AbbVie partnership headlines promising obesity pipeline: 09.05. Gubra-Aktie: Kann sie sich verdoppeln?

Obesity research and facts. Read the latest medical research on obesity. Evaluate weight loss programs and choose a diet plan based on your health and lifestyle needs.

But for those living with obesity, who are known to exhibit differences in walking gait, speed, energy burned ... Jun 19, 2025 1. 55. People make riskier choices when stressed, and here's why. 10 ...

Obesity is a chronic and progressive disease with medical, physical, and psychosocial comorbidities. To manage obesity and reduce obesity-related health risks, lifestyle intervention, featuring ...

HORSHOLM, DENMARK / ACCESS Newswire / June 27, 2025 / On Friday, 27 June 2025 at 12:00 am (CEST), an extraordinary general meeting of Gubra A/S (CPH:GUBRA) (the "Company") was held at the Company's ...